Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6889759 | 0.85 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1KDM4ECYP1A2MAPT | |
| SCHEMBL9729781 | 0.84 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1KDM4ECYP1A2MAPT | |
| SCHEMBL1733527 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KDM4ECYP1A2MAPT | |
| SCHEMBL30002312 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KDM4ECYP1A2MAPT | |
| SCHEMBL3281879 | 0.84 | KDM4E (0.60) | SMN1; SMN2ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL2222620 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1KDM4ECYP1A2MAPT | |
| SCHEMBL23202573 | 0.82 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1KDM4ECYP1A2MAPT | |
| SCHEMBL30474276 | 0.82 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1KDM4ECYP1A2MAPT | |
| SCHEMBL23198535 | 0.82 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1KDM4ECYP1A2MAPT | |
| SCHEMBL31254231 | 0.82 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1KDM4ECYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9522926-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2663553-B1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORP (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-30 | — | — | US | disclosed |
| US-8940927-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2185570-B1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS INC (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2663553-A2 | QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-07 | — | — | US | disclosed |
| US-20100179150-A1 | ANTIBACTERIAL PIPERDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| CN-101712688-A | Hybrid QA molecules wherein Q is an aminoquinoline and A is an antibiotic residue, their synthesis and their uses as antibacterial agent | PALUMED SA | 2010-05-26 | — | — | CN | disclosed |
| EP-2185570-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | Metabasis Therapeutics, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009023718-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| EP-1853586-A1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| CN-101068821-A | Hybrid QA molecules where Q is an aminoquinoline and A is an antibiotic residue, their synthesis and use as antibacterial agents | PALUMED SA (FR) | 2007-11-07 | — | — | CN | disclosed |
| EP-1771456-A2 | HYBRID QA MOLECULES WHEREIN Q IS AN AMINOQUINOLINE AND A IS AN ANTIBIOTIC RESIDUE, THEIR SYNTHESIS AND THEIR USES AS ANTIBACTERIAL AGENT | Palumed SA (FR) | 2007-04-11 | — | — | EP | disclosed |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | PALUMED S.A. (FR) | 2007-03-15 | — | — | US | disclosed |
| WO-2006087543-A1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006024741-A2 | HYBRID QA MOLECULES WHEREIN Q IS AN AMINOQUINOLINE AND A IS AN ANTIBIOTIC RESIDUE, THEIR SYNTHESIS AND THEIR USES AS ANTIBACTERIAL AGENT | PALUMED S.A. (FR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005805-B2 | — | GCKR, GCK, HK1 | SMN1; SMN2 3089/4885ALDH1A1 1843/4885KDM4E 4072/4885 |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | SMN1; SMN2 3652/4885ALDH1A1 2389/4885KDM4E 3996/4885 |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | QARS1, QPCT, QTRT2 | SMN1; SMN2 4858/4885ALDH1A1 2264/4885KDM4E 2016/4885 |
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | JAK3, JAK2, JAK1 | SMN1; SMN2 3139/4885ALDH1A1 4518/4885KDM4E 1365/4885 |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | SMN1; SMN2 3652/4885ALDH1A1 2389/4885KDM4E 3996/4885 |
| US-20100179150-A1 | ANTIBACTERIAL PIPERDINE DERIVATIVES | PIR, HAMP, AMPD2 | SMN1; SMN2 3190/4885ALDH1A1 502/4885KDM4E 3484/4885 |
| US-10174062-B2 | Activators of glucokinase | GCKR, GCK, HK1 | SMN1; SMN2 3576/4885ALDH1A1 2263/4885KDM4E 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.